CORRELATION ANALYSIS OF THE INCIDENCE OF POSTVIRAL SYNDROME WITH COMPARATIVE DATA OF ANTIVIRAL DRUGS
Article Sidebar
Main Article Content
Abstract
In this article, we performed a correlation analysis between the incidence of postcovirus syndrome and the use of antiviral drugs in patients. Comparative data on the use of antiviral drugs in different groups of patients, with different clinical manifestations in patients hospitalized with this pathology were used. This analysis allowed us to detect a non-significant correlation between groups with the use of different antiviral drugs. Moreover, our results confirmed the importance of early use of antiviral therapy to prevent the development of postviral syndrome. The results obtained are an important step in increasing the efficiency of diagnosis and treatment of post-Covid syndrome, and also contribute to the more effective use of antiviral therapy in clinical practice.
Article Details
References
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020.
Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am J Chin Med. 2020:1-26.
Yin-Xiao Du, Xiao-Ping Chen. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection // Clinical pharmacology and therapeutics. — 2020. — April 4.
Kimiyasu Shiraki, Tohru Daikoku. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections // Pharmacology & Therapeutics. — 2020. — May (vol. 209). - P. 107512.
A team of authors led by L.N. Tuychiev. Temporary guidelines for the diagnosis and treatment of coronavirus infection. Tashkent 09/08/2020
Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral research. 2019; 167:45-67.
Gordon C. J., Tchesnokov E. P., Feng J. Y., Porter D. P., Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. // The Journal Of Biological Chemistry. — 2020. — April 10 (vol. 295, no. 15). — P. 4773—4779.
Agostini M. L., Andres E. L., Sims A. C., Graham R. L., Sheahan T. P., Lu X., Smith E. C., Case J. B., Feng J. Y., Jordan R., Ray A. S., Cihlar T., Siegel D., Mackman R. L., Clarke M. O. , Baric R. S., Denison M. R. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. (English) // MBio. — 2018. — March 6 (vol. 9, no. 2).
Sheahan T. P., Sims A. C., Graham R. L., Menachery V. D., Gralinski L. E., Case J. B., Leist S. R., Pyrc K., Feng J. Y., Trantcheva I., Bannister R., Park Y., Babusis D., Clarke M. O., Mackman R. L., Spahn J. E., Palmiotti C. A., Siegel D., Ray A. S., Cihlar T., Jordan R., Denison M. R., Baric R. S. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses // Science Translational Medicine. — 2017. — June 28 (vol. 9, no. 396)
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet2020; 395:1054-62.
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol2020; 5:802-10.
Puntmann VO, Karerge ML, Wieters I, et al. Cardiovascular magnetic resonance imaging findings in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol2020; 5:1265-73.
Carfi A, Bernabei R, Landi F, Gemelli COVID-19 Post-Acute Care Study Group. Gemelli v. C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA2020; 324:603-5.
Rajpal S, Tong MS, Borchers J . Cardiovascular magnetic resonance findings in athletes recovering from COVID-19 infection. JAMA Cardiol2021; 6:116-8.
Johansson M, Stolberg M, Runold M, et al. Long-term symptoms after COVID-19 manifesting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep2021; 3:573-80. DOI:10.1016/J.Jaccas.2021
Dani M., Dirksen A., Taraborrelli. et al. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies. Clean Med (London)2021; 21:E63-7.